Chronic Kidney Disease
Conditions
Keywords
glomerular filtration rate, hypertension
Brief summary
The purpose of this study is to compare the effect of fosinopril plus benidipine vs. fosinopril plus hydrochlorothiazide on the renal function during the 6-month treatment in CKD patients with HTN.
Detailed description
Patients with chronic kidney dysfunction or injury which affected the health over three months were diagnosed with chronic kidney disease (CKD).China has a high prevalence of CKD.The prevalence, awareness, and treatment of hypertension (HTN) in non-dialysis CKD patients were 67.3%,85.8%, and 81.0%, respectively. The renin-angiotensin system inhibitors (RASI) including angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1 receptor blocker (ARB) have been deeply confirmed to have apparent reno-protective effect in patients with CKD.Co-administration of diuretics and calcium channel blockers (CCBs) with ACEIs or ARBs are the most common combinations. Hydrochlorothiazide plus RASIs are another widely used combination according to the synergetic function of antihypertensive action and offset mutual adverse effects. Until now, no large scale studies have compared the effect of initial treatment with two different combinations of antihypertensive drugs in CKD patients on the progression of kidney disease in China. Studies in the subsets of CKD (diabetes and non-diabetes, micro-albuminuria and macro-albuminuria) are urgently needed.We aimed to conduct a large scale study to compare L/T-type CCB and diuretic on the basis of ACEI in CKD with HTN on renal progression of CKD in China.
Interventions
DRUGFosinopril
Fosinopril is an angiotensin-converting enzyme inhibitor.
DRUGBenidipine
Benidipine is a dihydropyridine-derived calcium channel blocker.
DRUGHydrochlorothiazide
Hydrochlorothiazide is a diuretic medication.
Sponsors
First Affiliated Hospital of Zhejiang University
Zhongda Hospital
Ruijin Hospital
The First Affiliated Hospital of Zhengzhou University
Sichuan Provincial People's Hospital
The Second Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Anhui Medical University
Shanghai Changzheng Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with non-dialysis CKD at the enrollment and randomization eGFR≥ 30 ml/min per 1.73 m2 at the enrollment and randomization SBP\> 130 mmHg and/or DBP \> 80 mmHg at the enrollment and randomization. Patients could not receive more than two antihypertensive medications prior to our enrollment, and should discontinue the prior antihypertensive medications after the enrollment according to the investigators' advice. 2. 24 h proteinuria \< 1.5g at the enrollment 3. Patients who signed the informed consent form 4. Baseline serum Cr \< 3 mg/dL at the enrollment and randomization
Exclusion criteria
1. Hypertensive crisis (SBP \> 180 mmHg and/or DBP\>110 mmHg) 2. Refractory hypertension (taking \> 2 antihypertensive drugs more than a month, SBP still \> 160mm Hg or DBP \> 100mmHg) 3. Baseline serum Cr \> 3 mg/dl, or kidney transplantation 4. Patients diagnosed as severe cardiac arrhythmia (severe extra beats, supraventricular tachycardias, ventricular arrhythmias, or bradyarrhythmias), heart failure, NYHA \>Ⅲ, angina, stroke, left ventricular hypertrophy or myocardial infarction within 12 months prior to first visit. 5. Patients diagnosed as cancer or severe sepsis 6. Hematological system disorders: myelodysplastic syndrome, granulocytopenia, hypereosinophilic syndrome, polycythemia, thrombocytopenia, and et al. 7. Restrictive pericarditis 8. Systemic Lupus Erythematous 9. Severe diabetes complications such as diabetic ketoacidosis, hyperosmolar coma, retinopathy, amputation, and et al. 10. Patients diagnosed as hyperkalemia(\>5.5mmol/L) within 6 months or at the enrollment 11. Renal artery stenosis or vascular embolism disease 12. Patient is currently pregnant or lactational 13. AST/ALT \> three times of the upper limit of standard value at the baseline 14. Any severe allergy of CCB, diuretic or ACE inhibitor 15. History of severe side effects of CCB, diuretic or ACE inhibitor; long-term use of non-steroidal anti-inflammatory drugs 16. Use of other investigational drugs within 30 days or 5 half-lives of last visit, whichever is longer. 17. Other unsuitable patients judged by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in estimated glomerular filtration rate | Changes in eGFR at month 6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in 24 hour proteinuria | From baseline to month 6 | — |
| Changes in mean SBP | From baseline to month 6 | — |
| Abnornal cardiovascular events | At month 6 | Number of participants with cardiovascular morbidity (nonfatal stroke, non-fatal myocardial infarction, resuscitated sudden cardiac death, unstable angina; and coronary revascularization procedures) and cardiovascular mortality (death due to sudden cardiac death, fatal stroke, fatal myocardial infarction, congestive heart failure or other cardiovascular causes). |
| Abnormal renal events | From baseline to month 6 | Number of participants with 30% reduction of eGFR, doubling of serum creatinine concentration,end-stage renal disease (eGFR\< 15 mL/min/1.73m²) or chronic dialysis. |
| Changes in urinary albumin excretion | From baseline to month 6 | — |
| Changes in mean DBP | From baseline to month 6 | — |
| Adverse Events | From baseline to month 6 | Number of participants with abnormal laboratory values and/or adverse events that are related to Treatment |
Countries
China
Contacts
Primary ContactChanglin Mei, MD
Outcome results
None listed